These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 8781766

  • 21. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T.
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [Abstract] [Full Text] [Related]

  • 24. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.
    Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW.
    Diabetes Care; 1998 Sep; 21(9):1455-61. PubMed ID: 9727891
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
    Patel J, Anderson RJ, Rappaport EB.
    Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
    [Abstract] [Full Text] [Related]

  • 30. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
    Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI.
    Diabetologia; 2000 Mar; 43(3):278-84. PubMed ID: 10768088
    [Abstract] [Full Text] [Related]

  • 31. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.
    Skillman CA, Raskin P.
    Diabetes Care; 1997 Apr; 20(4):591-6. PubMed ID: 9096985
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
    Maruyama S, Yanagisawa K, Kanamuro R, Teno S, Iwamoto Y.
    Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
    [Abstract] [Full Text] [Related]

  • 36. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
    Katsuki A, Sumida Y, Murata K, Furuta M, Araki-Sasaki R, Tsuchihashi K, Hori Y, Yano Y, Gabazza EC, Adachi Y.
    Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
    [Abstract] [Full Text] [Related]

  • 37. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
    Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M.
    Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
    [Abstract] [Full Text] [Related]

  • 38. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients.
    Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M.
    Diabetes Care; 1998 Sep; 21(9):1470-4. PubMed ID: 9727893
    [Abstract] [Full Text] [Related]

  • 39. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients.
    Cominacini L, Garbin U, Fratta Pasini A, Campagnola M, Davoli A, Foot E, Sighieri G, Sironi AM, Lo Cascio V, Ferrannini E.
    Diabetes; 1998 Jan; 47(1):130-3. PubMed ID: 9421387
    [Abstract] [Full Text] [Related]

  • 40. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.
    Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y.
    Diabetes Res Clin Pract; 1991 Mar; 11(3):147-53. PubMed ID: 2036936
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.